Investing.com - Financial Markets Worldwide

GlobeImmune Inc (GBIM)

OTC Markets
Currency in USD
0.001
0.000(0.00%)
Closed·
GBIM Scorecard
Full Analysis
Stock generally trades with high price volatility
Trading near 52-week High
Trading near 52-week Low
GBIM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.0010.001
52 wk Range
0.0010.001
Key Statistics
Edit
Prev. Close
-
Open
0.001
Day's Range
0.001-0.001
52 wk Range
0.001-0.001
Volume
-
Average Volume (3m)
600
1-Year Change
42.86%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GBIM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 9
Suffers from weak gross profit margins
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

GlobeImmune Inc Company Profile

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of NantCell, Inc.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
3
Market
United States

Compare GBIM to Peers and Sector

Metrics to compare
GBIM
Peers
Sector
Relationship
P/E Ratio
0.0x−3.1x−0.6x
PEG Ratio
0.000.000.00
Price/Book
0.0x1.4x2.6x
Price / LTM Sales
0.0x9.0x3.3x
Upside (Analyst Target)
0.0%196.9%37.4%
Fair Value Upside
Unlock−2.8%4.5%Unlock

Earnings

Latest Release
May 12, 2016
EPS / Forecast
-0.15 / --
Revenue / Forecast
942.75K / --
EPS Revisions
a
a
Unlock
Last 90 days

GBIM Income Statement

FAQ

What Stock Exchange Does GlobeImmune Trade On?

GlobeImmune is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for GlobeImmune?

The stock symbol for GlobeImmune is "GBIM."

What Is the GlobeImmune Market Cap?

As of today, GlobeImmune market cap is 5.75K.

What Is GlobeImmune's Earnings Per Share (TTM)?

The GlobeImmune EPS (TTM) is -0.36.

From a Technical Analysis Perspective, Is GBIM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GlobeImmune Stock Split?

GlobeImmune has split 0 times.

How Many Employees Does GlobeImmune Have?

GlobeImmune has 3 employees.

What is the current trading status of GlobeImmune (GBIM)?

As of 25 Aug 2025, GlobeImmune (GBIM) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 0.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.